INMED PHARMACEUTICALS INC. (INM)

Every figure this model derived for INM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquirePropertyPlantAndEquipment 2025-06-30
cash 5,200,557 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 6,888,081 AssetsCurrent 2026-03-31
current liabilities 2,211,266 LiabilitiesCurrent 2026-03-31
equity 6,891,774 StockholdersEquity 2026-03-31
interest expense 0 InterestPaidNet 2025-06-30
ocf -7,457,501 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 4,506,597 Revenues 2025-12-31
sbc 110,970 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up INM on one particular measure came for.

RatioValue
current ratio3.11
current ratio reported3.11
deferred revenue growth81.66
dilution pct156.29
fcf margin-165.48
growth cv1.98
owner earnings margin-167.94
revenue growth-6.73
revenue growth per share-63.61
sbc pct revenue2.46

What to be careful about

What this model itself distrusts about INM's figures. Written by the derivation as it ran, not added afterwards.